Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Hypomethylating agents decitabine and azacytidine are regarded as interchangeable in the treatment of acute myeloid leukemia (AML). However, their mechanisms of action remain incompletely understood, and predictive biomarkers for HMA efficacy are lacking. Here, we show that the bioactive metabolite...

Descripción completa

Detalles Bibliográficos
Autores principales: Oellerich, Thomas, Schneider, Constanze, Thomas, Dominique, Knecht, Kirsten M., Buzovetsky, Olga, Kaderali, Lars, Schliemann, Christoph, Bohnenberger, Hanibal, Angenendt, Linus, Hartmann, Wolfgang, Wardelmann, Eva, Rothenburger, Tamara, Mohr, Sebastian, Scheich, Sebastian, Comoglio, Federico, Wilke, Anne, Ströbel, Philipp, Serve, Hubert, Michaelis, Martin, Ferreirós, Nerea, Geisslinger, Gerd, Xiong, Yong, Keppler, Oliver T., Cinatl, Jindrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677770/
https://www.ncbi.nlm.nih.gov/pubmed/31375673
http://dx.doi.org/10.1038/s41467-019-11413-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677770/
https://www.ncbi.nlm.nih.gov/pubmed/31375673
http://dx.doi.org/10.1038/s41467-019-11413-4

Ejemplares similares